Holen Sie sich die Stockscreener-App
6.51
2.36%
0.15
Handel nachbörslich:
6.52
0.010
+0.15%
Schlusskurs vom Vortag:
$6.36
Offen:
$6.35
24-Stunden-Volumen:
1.45M
Relative Volume:
0.65
Marktkapitalisierung:
$662.39M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-29.07M
KGV:
-22.45
EPS:
-0.29
Netto-Cashflow:
$-31.85M
1W Leistung:
+3.50%
1M Leistung:
+3.17%
6M Leistung:
+126.04%
1J Leistung:
+151.35%
1-Tages-Spanne:
$6.20
$6.60
1-Wochen-Bereich:
$6.08
$6.60
52-Wochen-Spanne:
$2.30
$7.39
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Firmenname
Trevi Therapeutics Inc
Sektor
Branche
Telefon
203-304-2499
Adresse
195 CHURCH STREET, NEW HAVEN, CT
Vergleichen Sie TRVI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
6.51 | 639.97M | 0 | -29.07M | -31.85M | -0.29 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-10 | Bestätigt | Needham | Buy |
| 2025-03-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-12-12 | Bestätigt | H.C. Wainwright | Buy |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-30 | Eingeleitet | Raymond James | Outperform |
| 2024-06-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-04-12 | Eingeleitet | B. Riley Securities | Buy |
| 2022-11-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-06-03 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-06-03 | Eingeleitet | Needham | Buy |
| 2019-06-03 | Eingeleitet | SVB Leerink | Outperform |
| 2019-06-03 | Eingeleitet | Stifel | Buy |
Alle ansehen
Trevi Therapeutics Inc Aktie (TRVI) Neueste Nachrichten
What is HC Wainwright’s Forecast for TRVI Q2 Earnings? - Defense World
H.C. Wainwright Initiates Coverage of Trevi Therapeutics (TRVI) With Buy Rating - MSN
Trevi Therapeutics to Participate in Upcoming June Conferences - Citizen Tribune
Trevi Therapeutics to Participate in Upcoming June Conferences | TRVI Stock News - GuruFocus
Trevi Therapeutics Reveals New Haduvio Data: Key Updates Coming at Major Medical Conferences - Stock Titan
Trevi Therapeutics (NASDAQ:TRVI) Coverage Initiated by Analysts at HC Wainwright - Defense World
H.C. Wainwright sets $21 target for Trevi Therapeutics stock By Investing.com - Investing.com Nigeria
HC Wainwright & Co. Initiates Coverage of Trevi Therapeutics (TRVI) with Buy Recommendation - Nasdaq
H.C. Wainwright sets $21 target for Trevi Therapeutics stock - Investing.com
HC Wainwright & Co. Initiates Coverage on Trevi Therapeutics (TRVI) with Buy Rating | TRVI Stock News - GuruFocus
H.C. Wainwright Commences Coverage on Trevi Therapeutics (TRVI) with Positive Outlook | TRVI Stock News - GuruFocus
Northern Trust Corp Raises Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Trevi Therapeutics (NASDAQ:TRVI) Earns “Buy” Rating from Needham & Company LLC - Defense World
Raymond James sets $29 target for Trevi Therapeutics stock By Investing.com - Investing.com Nigeria
Trevi Therapeutics (TRVI): Analyst Reiterates Buy Rating with $2 - GuruFocus
Stifel maintains Buy on Trevi Therapeutics, $15 target By Investing.com - Investing.com Nigeria
Trevi Therapeutics (TRVI): Analyst Reiterates Buy Rating with $24 Price Target | TRVI Stock News - GuruFocus
Trevi Therapeutics, Inc. Announces Additional Analyses from Phase 2A River Trial of Haduvio in Patients with Refractory Chronic Cough - marketscreener.com
Trevi Therapeutics Announces Additional Analyses from Phase 2a R - GuruFocus
Trevi Therapeutics (TRVI) Reveals New Findings from Phase 2a RIV - GuruFocus
Trevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough | TRVI Stock News - GuruFocus
Trevi Therapeutics (TRVI) Reveals New Findings from Phase 2a RIVER Trial | TRVI Stock News - GuruFocus
Trevi Therapeutics Announces Additional Analyses From Phase 2A River Trial Of Haduvio In Patients With Refractory Chronic Cough - marketscreener.com
Trevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough - PR Newswire
Prurigo Nodularis Market on Track for Major Expansion by 2034, According to DelveInsight | Celgene Crp., Novartis, Pfizer, Galderma, Genentech, Incyte Crp., Trevi Therapeutics, Vyne Therapeutics - The Globe and Mail
Price T Rowe Associates Inc. MD Has $104,000 Stock Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Dimensional Fund Advisors LP Grows Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
12,000 Shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI) Purchased by Raymond James Financial Inc. - Defense World
Wall Street Analysts See a 195.05% Upside in Trevi Therapeutics (TRVI): Can the Stock Really Move This High? - Yahoo Finance
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2025 Earnings Call Transcript - Insider Monkey
Wells Fargo & Company MN Buys 9,562 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates - Seeking Alpha
Trevi Therapeutics Reports Q1 2025 Results and Updates - TipRanks
MetLife Investment Management LLC Purchases 19,857 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Trevi Therapeutics Inc (TRVI) Q1 2025 Earnings Call Highlights: Promising Trial Results and ... - Yahoo Finance
Earnings call transcript: Trevi Therapeutics beats Q1 2025 EPS expectations By Investing.com - Investing.com UK
Earnings call transcript: Trevi Therapeutics beats Q1 2025 EPS expectations - Investing.com
Trevi Therapeutics (TRVI): Promising Data and Strategic Advances - GuruFocus
Trevi Therapeutics (TRVI): Promising Data and Strategic Advances | TRVI Stock News - GuruFocus
Trevi Therapeutics Inc (TRVI) Q1 2025 Earnings: EPS of -$0.09 Beats Estimate, Reports $10.3 Million Net Loss - GuruFocus
Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates | TRVI Stock News - GuruFocus
Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates - Stock Titan
Barclays PLC Boosts Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Market Insights: Trevi Therapeutics Inc (TRVI)’s Notable Gain of 1.22, Closing at 6.66 - DWinneX
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Rating of “Buy” from Analysts - Defense World
Trevi Therapeutics Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
Invesco Ltd. Boosts Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Renaissance Technologies LLC Acquires 29,700 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Trevi Therapeutics (TRVI) to Release Quarterly Earnings on Tuesday - Defense World
Trevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025 - StreetInsider
Trevi Therapeutics to Report First Quarter 2025 Financial Result - GuruFocus
Finanzdaten der Trevi Therapeutics Inc-Aktie (TRVI)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
3.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):